InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Cardiology and Cardiovascular Medicine » "Cardiomyopathies - Types and Treatments", book edited by Kaan Kirali, ISBN 978-953-51-3040-6, Print ISBN 978-953-51-3039-0, Published: April 12, 2017 under CC BY 3.0 license. © The Author(s).

Chapter 7

Cardiomyopathy Caused by Mutations in Nuclear A-Type Lamin Gene

By Gisèle Bonne and Antoine Muchir
DOI: 10.5772/65315

Article top


Cellular localizations of proteins involved in dilated cardiomyopathies.
Figure 1. Cellular localizations of proteins involved in dilated cardiomyopathies.
Cardiac symptoms of ?LMNA cardiomyopathy (A) and pathological mechanisms (B).
Figure 2. Cardiac symptoms of ?LMNA cardiomyopathy (A) and pathological mechanisms (B).
Nuclear lamins: structure (A), organization (B), and cellular localization (C). Modified from [10].
Figure 3. Nuclear lamins: structure (A), organization (B), and cellular localization (C). Modified from [10].

Cardiomyopathy Caused by Mutations in Nuclear A-Type Lamin Gene

Gisèle Bonne and Antoine Muchir
Show details


Heart disease is a major cause of morbidity and premature mortality. Cardiomyopathy is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, often leading to heart failure–related disability. Dilated cardiomyopathy caused by mutations in A-type lamin gene (i.e., LMNA cardiomyopathy) is characterized by an increase in both myocardial mass and volume. The ventricular walls become thin and stretched, compromising cardiac contractility and ultimately resulting in poor left ventricular function. Despite current strategies to aggressively manage “LMNA cardiomyopathy,” the disorder remains a common cause of heart failure with decreased ejection fraction, and a prevalent diagnosis in individuals is referred for cardiac transplantation. Despite progress in reducing “LMNA cardiomyopathy”–related mortality, hospitalizations remain very frequent and rates of readmission continue to rise. It appears important and necessary to further increase our knowledge on the pathophysiology of “LMNA cardiomyopathy” to unveil novel molecular/cellular mechanisms to target future therapeutic approaches.

Keywords: Dilated cardiomyopathy, Genetics, LMNA, A-type lamins, Nuclear lamina

1. Introduction

Cardiomyopathy, a major cause of morbidity and premature mortality in developed countries, is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, often leading to heart failure-related disability, which is a staggering clinical and public health problem. The mechanical component of the heart is liable for pumping blood throughout the body. The electric component, as for it, produces a rhythm for the blood to be pumped correctly. Hence, both components are tightly connected and regulated. Most common symptoms of dilated cardiomyopathy are shortness of breath, leg swelling, decreased exercise tolerance, fatigue, dizziness, coughing or wheezing, weight gain, and palpitation. Given the diversity in severity of symptoms in dilated cardiomyopathy, the disease is not always diagnosed. Cardiomyopathies are a clinically heterogeneous group of cardiac muscle disorders [1]. Cardiomyopathies have historically been broken down into several major phenotypic categories. Dilated cardiomyopathy, the most common form, is a condition where the heart muscle becomes enlarged and weakened, resulting in poor left ventricular function. Despite current strategies to aggressively manage dilated cardiomyopathy, the disorder remains a common cause of heart failure with a decrease below 45 % of ejection fraction and a referring for cardiac transplantation. Notwithstanding progress in reducing heart failure-related mortality, hospitalizations for heart failure remain very frequent and rates of readmissions continue to rise. It appears important and necessary to increase our knowledge on the pathophysiology of cardiomyopathies to unveil novel molecular/cellular mechanisms for future therapeutic approaches.

2. Inherited cardiomyopathies

While the most common cardiomyopathies are secondary to acquired conditions, many are inherited. Genetic mutations have been identified in 25–35 % of patients presenting dilated cardiomyopathy. These mutations affect genes that encode components of a wide variety of cellular compartments and pathways, including the nuclear envelope (e.g., LMNA, EMD), the contractile apparatus (e.g., MYH7, ACTC1, TPM1, TTN), the force transduction apparatus (e.g., MLP, DES, TNNT2), and calcium handling (e.g., SERCA). The cardiac cell is composed of a complex network of proteins linking the sarcomere to the sarcolemma and the extracellular matrix, providing structural support for subcellular structures and transmitting mechanical signals within and between cells (Figure 1). Mutations in genes encoding proteins of the sarcolemma are disrupting the anchoring and hence abrogate the transmission of the force generated by muscle contraction. Muscle contraction is due to the interaction between an actin filament and myosin heavy chain. Mutations in genes encoding contractile elements were identified as the cause of dilated cardiomyopathy. Functional units of striated muscle are called sarcomeres. Because the generated power of muscle contraction is transmitted to adjacent sarcomeres through the Z-disk, mutations in genes encoding proteins of the Z-disk causes also dilated cardiomyopathy. Part of hereditary dilated cardiomyopathies is caused by mutations in the genes encoding proteins of the nuclear envelope. Hence, disruption of the links from the sarcolemma to the sarcomere and nucleus could have a “domino effect,” which leads to the disruption of systolic function and to the development of dilated cardiomyopathy.


Figure 1.

Cellular localizations of proteins involved in dilated cardiomyopathies.

3. LMNA cardiomyopathy

Among the causing genes of dilated cardiomyopathy, it has been estimated that mutations in LMNA, encoding nuclear lamin A/C [2], accounts for about 5–10 % of familial dilated cardiomyopathy, thus representing one of the major causative genes. Affected patients often exhibit early conduction defects before left ventricle dysfunction and dilatation occur [3]. “LMNA cardiomyopathy” usually presents in early to mid-adulthood with symptomatic conduction system disease or arrhythmias or with symptomatic dilated cardiomyopathy (Figure 2A). “LMNA cardiomyopathy” has an intrusive clinical progression with higher rates of aggressive arrhythmias and faster course toward heart failure than most other cardiac diseases. Given the increased awareness among physicians, cardiologists are now facing difficult queries regarding patient management. These queries concern the use of defibrillators in order to avoid sudden death from aggressive ventricular arrhythmias and pharmacological interventions to improve heart failure symptoms. Once dilated cardiomyopathy is detected clinically, the management for “LMNA cardiomyopathy” follows the standard of care for heart failure. It is unclear whether early institution of these therapeutic agents prior to detectable cardiac dysfunction can modify the aggressive nature of “LMNA cardiomyopathy.” There is no definitive treatment for the progressive cardiac dilatation and loss of contractility in “LMNA cardiomyopathy” short of heart transplantation [4].


Figure 2.

Cardiac symptoms of ?LMNA cardiomyopathy (A) and pathological mechanisms (B).

4. A-type nuclear lamins

The LMNA gene, on chromosome 1q21.2-21.3, encodes nuclear A-type lamins. Lamin A and lamin C, the major somatic A-type lamins, arise via alternative splicing of pre-mRNA [5] (Figure 3A). Lamin A is primarily synthesized as a precursor, the prelamin A. Prelamin A has a particular C-terminal amino acid tail, which undergoes several enzymatic reactions to produce mature lamin A. Two other genes, LMNB1 and LMNB2, encode lamins B1 and B2, respectively. Lamins are class V intermediate filament proteins that polymerize to form the nuclear lamina (Figure 3B), a fibrous network underlining the inner nuclear membrane of most eukaryotic cells (Figure 3C) [68]. The nuclear lamina is bounded to the inner nuclear membrane via interactions with integral proteins and to the chromatin. It has also been shown that lamin A/C can also interact with the cytoskeleton, through the linker of nucleoskeleton and cytoskeleton (“LINC”) complex [9]. One function of the lamina is to provide structural support to the nucleus. Nuclear lamins have also been implicated in processes such as chromatin organization, gene regulation, DNA replication, and RNA splicing [10]. However, the specific mechanistic roles of lamins in these processes, particularly in a cell- or tissue-type–specific context, remain obscure.


Figure 3.

Nuclear lamins: structure (A), organization (B), and cellular localization (C). Modified from [10].

5. Pathogenesis

Identification of disease-causing mutations in the heart has contributed to the delineation of “LMNA cardiomyopathy.” However, much work remains in elucidating the specific cellular mechanisms of the disease. Several hypotheses have been proposed attempting to link the pathophysiology of “LMNA cardiomyopathy” to known or emerging functions of lamin A/C. Among these functions include those based on that lamin A/C likely have in maintaining the mechanical integrity of cells subject to external and internal cues and signal transduction (i.e., the mechanical stress hypothesis). The “mechanical stress hypothesis” is attractive when trying to explain striated muscle diseases. It is based on the premise that the striated muscles are constantly subjected to mechanical forces and that mutations in “nucleocytoskeletal” support elements make them susceptible to damage from recurrent stress. Mouse models have been extremely helpful in deciphering crucial mechanisms, which could partially explain the pathogenesis of the disease. The development of Lmna−/− mice by Sullivan and colleagues was the first animal model of the disease [11]. Since, other models (knock-in and transgenic) have been created to study the cardiac dysfunction caused by LMNA mutation [1215]. We and others reported an aberrant cardiac activation of signaling pathways in “LMNA cardiomyopathy” [16, 17] in mice and human, which participate to the development of contractile dysfunction (mitogen-activated protein kinase (MAPK) signaling, AKT/mTOR signaling, TGF-β signaling, etc.) [16, 18, 19] and electrical disturbances (connexin 43 remodeling, apoptosis, Hf1b expression) (Figure 2B).

MAPK signaling—One of the most prevalent and best-characterized responses to mechanical stress is the phosphorylation of proteins, which could be mediated by mitogen-activated protein kinase (MAPK) signaling pathway. Genes encoding proteins in MAPK signaling pathway demonstrated significantly altered expression in hearts of Lmna H222P mice by transcriptomic analysis [16]. We demonstrated an aberrant activation of ERK1/2, JNK, and p38α signaling, three main branches of MAPK signaling pathway involved in cellular mechanotransduction, in hearts from Lmna H222P mice, as early as 4 weeks of age [16, 17]. Our work proved that the activation of MAPK signaling pathway preceded the cardiac dysfunction of Lmna H222P mice and that it is a consequence of alterations in lamin A/C and not secondary to nonspecific effects. Accordingly, lamin A/C-deficient fibroblasts subjected to cyclic strain respond with decreased expression of the mechanosensitive genes, which are downstream targets of the MAPK pathway [20].

AKT/mTOR signaling—We showed that the Lmna pH222P mutation results in aberrant activation of the AKT/mTOR signaling cascade, downstream of the MAPK pathway [18]. Given that activated mTOR inhibits autophagic responses and reduces tolerance to energy deficits, the heart is therefore unable to compensate for increased energy demand and, over time, develops muscle damage and dilated cardiomyopathy.

TGF-β signaling—Cardiac fibrosis exacerbates the clinical progression of heart failure. We showed that Lmna H222P mice had elevated expression of TGF-β signaling as early as 12 weeks of age, which is a time that preceded development of both cardiac fibrosis and the onset of overt cardiac dysfunction [13, 19]. Our observations indicate that TGF-β is a mediator of the cardiomyopathy that develops as a result of LMNA mutations.

Connexin 43 remodeling—Gap junction communications describe the electrical coupling of cells through specialized cell contacts called gap junctions. In adult heart, connexin 43 is expressed in the atrial and ventricular working (contractile) myocardium. The working cardiomyocytes of the ventricle are extensively interconnected by clusters of connexin 43 located at the intercalated disks. The intercalated disks of working ventricular myocardium have a step-like configuration, with the gap junctions situated predominantly in the “horizontal” facing segments of these steps rather than the vertical segments [21, 22]. Features of gap junction organization encourage preferential propagation of the impulse in the longitudinal axis, thus contributing to the normal pattern of anisotropic spread of the impulse of healthy ventricular myocardium. The most striking form of structural remodeling connexin 43 is typically scattered in disordered fashion over the lateral surfaces in the heart from Lmna N195K mice (i.e., lateralization) [12].

Apoptosis—Apoptosis in all metazoan cells is mediated by caspases, a multigene family of cysteine proteases that hydrolyzes peptide bonds carboxyl to aspartic acid residues. Once activated, caspases cut cellular proteins, leading to the apoptotic demise of the cell. During the past few years, there has been accumulating evidence in both human and animal models suggesting that apoptosis may be an important mode of cell death during heart failure [23]. Myocyte apoptosis has been reported in the atrioventricular tissue from Lmna+/− mice [24], which could account for the evolution of electrophysiologic dysfunction.

Hf1b/Sp4—This transcription factor has been described as important for the development of the cardiac conduction system [25]. Mounkes and colleagues found that expression and localization of Hf1b/Sp4 were altered in the heart from Lmna N195K mice [12]. Strikingly, this study reported that Hf1b/Sp4 was not found in the ventricles and was strongly expressed in the atria in the heart from Lmna N195K mice, which mirror the localization in control animals. This finding needs further analysis.

The exact mechanisms by which defects in nuclear lamins cause dysregulated signaling remain to be elucidated.

6. Treatments

Advances in molecular techniques have improved the understanding of mechanisms responsible for cardiac dysfunction in “LMNA cardiomyopathy.” It is clear that mutations in nuclear lamin A/C in cardiomyocytes can perturb cardiac function. Alterations in cardiomyocyte function initiate cascades of cellular responses that attempt to compensate for these insults. However, persistent responses at the cellular level lead to organ-wide alterations, which correlated with sudden cardiac death and heart failure. Although there exists no treatment to directly address the causes of “LMNA cardiomyopathy,” basic studies of the processes that mediate cellular responses to cardiac stress have allowed the development of innovative treatments that address the reduction of symptoms that include drugs that decrease blood pressure (ACE inhibitors, angiotensin II receptor blockers, beta-blockers) and heart rate (beta-blockers, calcium channel blockers, digoxin) to reduce the strain on the ventricular walls. Utilization of animal and cellular models to further dissect the mechanisms of “LMNA cardiomyopathy” and demonstrate efficacy of drugs that specifically target disease-causing pathways holds promise that further reduction in the mortality associated with “LMNA cardiomyopathy” can be achieved [1719, 26, 27].

7. Conclusion

In the past decade, there has been an extraordinary burst of researches on lamin A/C and the nuclear lamina, which has been accelerated by attempts to explain the pathogenesis of “LMNA cardiomyopathy.” One important unanswered question is how mutations in genes expressed in most differentiated somatic cells lead to human disease affecting the cardiac tissue. Within the next several years, we will likely have more clues to answer this question, and these answers will hopefully lead to new ways to treat or prevent “LMNA cardiomyopathy.”


1 - Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816. DOI: 10.1161/CIRCULATIONAHA.106.174287
2 - Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Müehle G, Johnson W, McDonough B: Missense mutation in the rod domain of he lamin A/C gene as cause of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715–1724. DOI: 10.1056/NEJM199912023412302
3 - Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D: Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209–210. DOI: 10.1056/NEJMc052632
4 - Ben Yaou R, Gueneau L, Demay L, Stora S, Chikaoui K, Richard P, Bonne G: Heart involvement in lamin A/C related diseases. Arch Mal Coeur Vaiss. 2006;99:848–855.
5 - Lin F, Worman HJ: Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 1993;268:16321–16326.
6 - Fisher DZ, Chaudhary N, Blobel G: cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A 1986;83:6450–6454.
7 - McKeon FD, Kirschner MW, Caput D: Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature 1986;319:463–468. DOI: 10.1038/319463a0
8 - Aebi U, Cohn J, Buhle L, Gerace L: The nuclear lamina is a meshwork of intermediate-type filaments. Nature 1986;323:560–564. DOI: 10.1038/323560a0
9 - Stewart CL, Roux KJ, Burke B: Blurring the boundary: the nuclear envelope extends its reach. Science 2007;318:1408–1412. DOI: 10.1126/science.1142034
10 - Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, Solimando L, Goldman RD: Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832–853. DOI: 10.1101/gad.1652708
11 - Sullivan T, Escalante-Alcade D, Bhatt H, Anver M, Bhat N, Nagashima K, Stewart CL, Burke B: Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol. 1999;147:913–920.
12 - Mounkes LC, Kozlov SV, Rottman JN, Stewart CL: Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet. 2005;14:2167–2180. DOI: 10.1093/hmg/ddi221
13 - Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacène E, Fromes Y, Toussaint M, Mura AM, Keller DI, Amthor H, Isnard R, Malissen M, Schwartz K, Bonne G: Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet. 2005;14:155–169. DOI: 10.1093/hmg/ddi017
14 - Wang Y, Herron AJ, Worman HJ: Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet. 2006;15:2479–2489. DOI: 10.1093/hmg/ddl170
15 - Cattin ME, Bertrand AT, Schlossarek S, Le Bihan MC, Jensen SS, Neuber C, Crocini C, Maron S, Lainé J, Mougenot N, Varnous S, Fromes Y, Hansen A, Eschenhagen T, Decostre V, Carrier L, Bonne G: Heterozygous Lmna delK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet. 2013;22:3152–3164. DOI: 10.1093/hmg/ddt172
16 - Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimura T, Bonne G, Worman HJ: Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J Clin Invest. 2007;117:1282–1293. DOI: 10.1172/JCI29042
17 - Muchir A, Reilly SA, Wu W, Iwata S, Homma S, Bonne G, Worman HJ: Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene. Cardiovasc Res. 2012;93:311–319. DOI: 10.1093/cvr/cvr301
18 - Choi JC, Muchir A, Wu W, Iwata S, Homma S, Morrow JP, Worman HJ: Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci Transl Med. 2012;4:144ra102. DOI: 10.1126/scitranslmed.3003875
19 - Chatzifrangkeskou M, Le Dour C, Wu W, Morrow JP, Joseph LC, Beuvin M, Sera F, Homma S, Vignier N, Mougenot N, Bonne G, Lipson KE, Worman HJ, Muchir A: ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutation in the lamin A/C gene. Hum Mol Genet. 2016;ddw090. DOI: 10.1093/hmg/ddw090
20 - Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT: Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest. 2004;113:370–378. DOI: 10.1172/JCI19670
21 - Severs NJ: Gap junction shape and orientation at the cardiac intercalated disk. Circ Res. 1989;65:1458–1461.
22 - Severs NJ: The cardiac gap junction and intercalated disc. Int J Cardiol. 1990;26:137–173.
23 - Kang PM, Izumo S: Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86:1107–1113.
24 - Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, Ahmad F, Sherwood M, Branco DM, Wakimoto H, Fishman GI, See V, Stewart CL, Conner DA, Berul CI, Seidman CE, Seidman JG: Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol. 2008;44:293–303. DOI: 10.1016/j.yjmcc.2007.11.008
25 - Nguyen-Tran VT, Kubalak SW, Minamisawa S, Fiset C, Wollert KC, Brown AB, Ruiz-Lozano P, Barrere-Lemaire S, Kondo R, Norman LW, Gourdie RG, Rahme MM, Feld GK, Clark RB, Giles WR, Chien KR: A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages. Cell 2000;102:671–682.
26 - Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ: Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet. 2009;18:241–247. DOI: 10.1093/hmg/ddn343
27 - Wu W, Muchir A, Shan J, Bonne G, Worman HJ: Mitogen activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by lamin A/C gene mutation. Circulation 2011;123:53–61. DOI: 10.1161/CIRCULATIONAHA.110.970673